RxDoctor Payments Data

Karanvir Kaur

Family · Fresno, CANPI 1811373897

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 39 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$687
  • Abbott$349
  • Pfizer$48
  • Medtronic$22
  • E.r. Squibb & Sons, L.L.C.$20
  • Novartis$19

What the payments were for

  • Food & beverage$1,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen30$687
Abbott3$349
Pfizer3$48
Medtronic1$22
E.r. Squibb & Sons, L.L.C.1$20
Novartis1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,144 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$1,170
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$121,695
EntrestoSacubitril/Valsartan21$26,520
Repatha SureclickEvolocumab25$23,776
XareltoRivaroxaban12$12,415
Metoprolol Succinate309$5,616
Amiodarone Hcl42$2,105
Rosuvastatin Calcium74$1,473
ClopidogrelClopidogrel Bisulfate87$1,383
Ezetimibe41$1,284
Atorvastatin Calcium125$1,247
Amlodipine Besylate161$1,173
Midodrine Hcl15$1,111
Isosorbide Mononitrate ErIsosorbide Mononitrate80$1,036
Losartan Potassium110$1,030
Potassium Chloride43$719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$121,69598 claims
NovartisEntresto$19$26,52021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →